Clinical Trial Update: A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis [Phase 3]

View source ↗

Summary

A Phase 3 trial of LX211 for posterior, intermediate, and pan-uveitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Intermediate Uveitis
• Panuveitis
• Posterior Uveitis

Drugs mentioned

• LX211

Snippet

Sponsor: Lux Biosciences, Inc. | Conditions: Uveitis, Posterior, Uveitis, Intermediate | Phase 3 | Status: COMPLETED